Speaker Profile
Ph.D., Global Product General Manager, Amgen
Biography
Sid Roychoudhury is a Global Product General Manager (GPGM) at Amgen where he leads multiple biologics development programs in immuno-oncology, including tarlatamab (AMG 757), a half-life extended DLL3-targeting BiTE (bispecific T cell engager) molecule under investigation for the treatment of small-cell lung cancer. Prior to joining Amgen in 2015, Sid spent ~12 years in various positions of increasing responsibilities in medical affairs, project management, external innovation, and finally as a Compound Development Team Leader (CDTL) in early development within the Immunology therapeutic area. Prior to J&J, Sid spent ~ 8 years in anti-bacterial drug discovery at Procter & Gamble Pharmaceuticals and led the discovery of TAIGEXYN®, a non-fluorinated quinolone, which is approved in multiple countries for the treatment of drug-resistant infections. Sid conducted his postdoctoral research at Eli Lilly & Company and holds a PhD in microbiology & immunology from University of Illinois College of Medicine in Chicago.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
